Author(s)

Mitzy E. Torres Soriano, Gerardo García Aguirre, Maximiliano Gordon Angelozzi, Veronica Kon Jara, Jans Fromow Guerra, Michael D. Ober, Hugo Quiroz Mercado

Centro de la Visión Gordon Manavella, Rosario, Argentina.
Department of Ophthalmology, University of North Carolina, Chapel Hill, USA.
Ophthalmology Service at Denver Health Medical Center, Denver, USA.
Retina Consultants of Michigan, Southfield, USA.
Retina Department, Asociación para evitar la Ceguera, Hos-pital Dr. Luis Sanchez Bulnes, Mexico City, Mexico.
Unidad Oftalmológica “Dr Torres López”, Centro Médico Cagua, Cagua, Venezuela.

Background: We report the use of intravitreal bevacizumab as an option for the treatment of chronic or recurrent central serous chorioretinopathy (CSC). Methods: Eight eyes with chronic or recurrent CSC received intravitreal bevacizumab (1.25 mg/0.05 cc) and underwent best corrected visual acuity (VA), optical coherent tomography (OCT), fluorescein angiography (FA) and indocyanine green angiography (ICG) before, and one, three and six months after treatment. Results: All patients showed improvement in visual acuity, fluorescein angiographic leakage, choroidal hyperpermeability and reduced or resolved neurosensory detachment following treatment. Two patients require a second dose of intravitreal bevacizumab. Conclusions: Intravitreal injection of bevacizumab was associated with visual improvement and reduced neurosensory detachment without adverse events in patients with chronic or recurrent CSC. Although these results are promising, further investigations would be helpful to understand this therapy for patients with CSC.

Central Serous Chorioretinopathy, Intravitreal Bevacizumab, Retinal Pigment Epithelium Detachment

Torres Soriano, M.E., García Aguirre, G., Gordon Angelozzi, M., Kon Jara, V., Fromow Guerra, J., Ober, M.D. and Quiroz Mercado, H. (2014) Intravitreal Bevacizumab for the Treatment of Chronic or Recurrent Central Serous Chorioretinopathy. Open Journal of Ophthalmology, 4, 57-64. doi: 10.4236/ojoph.2014.43010.